… a link between T2D and neurodegenerative disease such as Parkinson’s disease (PD)
and Alzheimer’s Disease (AD). Neurodegenerative diseases have a considerable physical, …

… neurodegenerative diseases, … neurodegenerative disease treatment. We propose that
repurposing already-approved GLP-1R agonists for the treatment of neurodegenerative diseases …

… 1 analogues such as liraglutide, exenatide and lixisenatide in neurodegenerative diseases.
… could play a role in some neurodegenerative diseases, such as AD, PD, Huntington’s …

… Aging is a crucial risk factor for common neurodegenerative diseases, such as Alzheimer's
disease (AD) and Parkinson's disease (PD). Limited options are available for the treatment of …

… that these aggregates play key roles in many diseases. In this review, wefocus attention on
… three feared neurodegenerative diseases: Alzheimer's,“mad cow,” and Huntington's disease, …

… treatment of type 1 diabetes mellitus in … -1 RA has the potential to treat neurodegenerative
diseases, particularly in diabetes-related Alzheimer’s disease (AD) and Parkinson’s disease (…

… peptides and their applications for the management of different diseases, but with focus on
neurodegenerative diseases. … QBP1, a polyQ binding peptide 1, was identified using a phage …

… of disease and the mechanisms triggering conformational changes in β-amyloid peptide …
and their role in the pathogenesis of neurodegenerative diseases. In addition, we discuss a …

… -like peptide 1 (GLP-1) facilitates insulin release during episodes of hyperglycaemia and
has several additional properties to overcome insulin desensitisation made GLP-1 an ideal …

… disease-related pathological conditions. One important example in neurodegenerative
diseases is the accumulation of amyloid-beta peptides (Aβ) in the brain of Alzheimer’s disease (…